The Highwire with Del Bigtree - THE RETURN OF HIV?

Episode Date: February 27, 2022

A new, highly virulent variant of HIV has suddenly popped up as the media is reporting everyone should be tested. Could there be a connection to Covid?#HIVvariant #AIDSVaccine #HIVBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

There's some headlines that are coming out that have us all falling off our chairs. We really don't know what to make of them. I did some digging into it. And so these are the headlines that are coming out just this week. Discovery of HIV variant shows virus can evolve to be more severe and contagious. So there was a recent cluster of about 17 samples, according to this article, that showed a lot of unusual mutations. 15 of those samples came from the Netherlands. And there was a study that was done.

So this study co-author, it says in this article here, his name is Chris Wyman. from the University of Oxford. He and his co-authors wanted to know more. So they dived into another Dutch study with more data. They discovered a total of 109 people who had this particular variant and never knew it. Dating all the way back to 1992, the variant probably emerged in the late 80s. Wyman says picking up steam around 2000 and then eventually slowing down around 2010. Goes on to say, people with this variant have a viral load that is three to four times higher than usual for those with HIV.

This characteristic means the virus progresses into serious illness twice as fast and also makes it more contagious. So stopping right there, when we're reading this, you start scratching your head because you go, wait a minute, these people have been carrying this, this highly contagious variant that goes into serious disease very quickly for 30 years and they didn't know it. Right. It didn't seem that serious. And I've been hearing people talk about this. Like did you hear about the virulent HIV that's sweeping the country right now? And so, you know, I'm glad you're looking into it. Right.

When you see stuff like that, now we've got to look into it because that doesn't make any sense. And so there's another headline right here. This is for heterosexual people. HIV now infects more heterosexual people than gay or bisexual men. We need a new strategy. Well, that's interesting. Why is it doing that? And then we have a Prince Harry comes out just recently and he says this on an interview.

Take a look. Every single one of us has a duty or at least an opportunity to, to, get tested ourselves to make it easier for everybody else to get tested. And then it just becomes a regular thing like anything else. But if we're not getting tested and we're like, oh, you know, HIV, that's not, how could that possibly affect me? That's affecting, you know, people over there. And it's like, no, it could affect you.

I mean, what happened to, you know, sort of safe sex campaigns and things like that? Now we're going to go into test it. We just got out of what, COVID testing. And now let's get into HIV testing. And maybe we can create a pandemic around this. Right. And they're talking about getting those HIV tests as commonly as COVID test. So again, you start looking at this and we got to wonder.

So it brought me back. It started thinking, we covered this before when it came to COVID. Where else have we heard about HIV during this COVID outbreak for the last two years? We dug into the archives. Take a look. The New York Post, mind-blowing headlines. Some COVID-19 vaccines could increase risk of HIV research. Now what they're talking about in this article, it centers around what's called the adenovirus.

And it's a common, it's a group of viruses that cause anything from flu-like symptoms, pink eye, common cold, bronchitis, pneumonia, things like that. Stuff were exposed to quite a bit, things people typically have symptoms for. And when they make these vaccines, they use a genetically modified version of this. It's called adenovirus type 585. And this is this specifically the viral vector vaccines we're talking about, like astiseneca's where they're using it, sort of like a capsule to, you know, deliver a gene and a message to the cells? Yeah, absolutely. They've tried this before over a decade ago in international studies for HIV acquisition. So they were, they had vaccines to prevent against HIV. And what they were finding was that men who were being vaccinated actually had a higher prevalence of HIV. And again, they were trying to stop HIV acquisition.

So they're finding that this vaccine, it makes men more susceptible, according to the data, for HIV. And let's look at the Lancet. So the Lancet came out with a correspondence. It was really a warning. And it said use of a Dinovirus type 5 vector vaccines, a cautionary tale. These are four veteran researchers. And they concluded, or I should say warned, on the basis of these findings,

we are concerned that use of an 85 vector for immunization against severe acute respiratory syndrome coronavirus 2 could similarly increase the risk of HIV-1 acquisition among men who received the vaccine. Wow. I mean, I remember we covered. I didn't remember exactly, you know, sort of how we'd looked at it. But, you know, that's right. I mean, there were warnings from top scientists using this technology could lead to an increased risk of H-Santis. which it's amazing putting that together right now when we look at the climate of how these headlines are coming out as we speak. Right. And just be clear, we're kind of just going into an open investigation here, throwing out all the cards in the table saying, this is what we found. Let's talk about it. And so, you know, it's hard to believe that was almost two years ago. But let's talk over the last two years, how many times HIV has come up in association with COVID-19 and this virus. So it really started in January 2020.

It didn't even have the name COVID-19 yet. It was still just this virus we found. It's starting to spread. It's in China. Some Indian researchers came out and published a paper. They looked at the genome of the virus that was circulating. And they called this paper uncanny similarity of unique inserts in a 2019 NCOVV-V-V spike protein to HIV-1, GP-120, and GAG. And they say, importantly, amino acid residues in.

all the four inserts have identity or similarity to those in the HIV-1 GP-120 or HIV-1-Gag. And so that paper is important. That was really the first sort of statement that suggested this may have been lab created. I mean, it came out super early. I remember talking about that. Maybe this came from a lab because it had this HIV sort of inserted protein in there. Right. And it's important to note that paper was retracted.

We really never heard from those authors again. on this topic. They just disappeared. At the same time, by the way, everybody that spoke of a lab origin was attacked. People, scientists were losing their license. We lost our YouTube channel. We lost our Facebook channel for discussing it. And now it's the number one reigning theory in the world by almost all of science. Right. Exactly. Great. That's a great point. And so on to Australia. Australia tried to make an in-house kind of vaccine just in their own continent. And they had to suspend that. And this was the headline here. This is still 2020. We're talking here. Australia halts local COVID-19 vaccine development due to false HIV positives. So what they were doing is they

were stabilizing the spike protein of the coronavirus with a small protein from HIV. It was acting like a clamp to stabilize and hold it together. And what that was doing was it was when these people got tested, the PCR test, they were showing these positives. And we were being told of false positives for HIV because they were picking up that residue and that immune response from from those from those points but now let's let's go from a little deeper from headline dot connecting into some actual some deeper science I should say so this is Forbes and this is kind of bringing it back picking back up where we left off in 2020 this is Forbes mainstream headline researchers warns some COVID-19 vaccines could increase risk of HIV infection and of course they're talking

about Merck's HIV step trial and Fambili study. These are the two studies that were in the Lancet that we talked about. Those are the authors that set out this warning in the Lancet. And they said basically the use of these adenovirus five-vector vaccines may cause HIV acquisition. That's what they found. So in like 2007, they were doing these studies in Africa and other parts of the world. And they found that, you know, just like I was speaking about in 2020, back to the future here, that was increasing the HIV acquisition among the people that were getting these vaccines. So these researchers came out in 2020 as the COVID vaccines were being produced. And they noticed that these adenovirus vectors were being used to produce COVID vaccines.

And they're saying, you don't want to do this. This is a caution because if you start using this in places like Africa or even United States, for that matter, that have high endemic HIV populations, it's going to exacerbate this issue, these infections. And so what we did here is we consulted our international scientific team and we started looking at studies here. And again, open investigation, but let's look at some of the studies that we found that are kind of cooperating this information. So one of the first studies here, this was from 2012. And this is looking at the title is Human Adinovirus specific T cells modulate HIV-specific T-cell responses to the AD5-vectored HIV-1 vaccine. Now we have a study from 2008, activation of dandritic cell,

T-cell axis by 85 immunocomplex creates an improved environment for replication of HIV in T-cells. A study from 2018, distinct susceptibility of HIV-vaccine-vector-induced CD-4 T-cells to HIV infection. So what this is, is, like we've talked about that, AD-5 vector, is being used in this vaccine development. And if someone has already been exposed to this common cold, basically a common coronavirus. The adenovirus is a common cold. They're using this vaccine. If you've already had that common cold, then you get this problem.

What is that problem exactly? What is the mechanism they're worried about? Yeah. Yes. And that is really talked about in this next study here. We'll dive into this study. This will really explain that. So the title of study here is adenovirus,

vector-specific T cells demonstrate a unique memory phenotype with high proliferation potential and co-expression of these are the two things you need to remember. CCR-5 and Integran Alpha-4-Beta-7. CCR-5 and Alpha-4 Beta-7 are receptors on these T cells. They act like docking stations. Okay. These T-cells displaying high levels of these docking stations on their surfaces, that people that have those are more likely to become infected with HIV. So basically it's building more docking stations for HIV to attach to the, you know, and to be clear, the studies weren't looking at, because these were HIV vaccines that might

have had HIV in the vaccine. They just separated out and did studies of just the adenovirus to see was that doing it without HIV. And this is what they're finding. There's increasing the amount of docking stations you have, or basically putting up antennas inside your body saying, come on over here if you're HIV, we've got a place for you to stay. Right, right. And these authors, let's read their conclusion. This is what they concluded. So this was, you know, again, this is all done in blood work in a petri dish, but they concluded

AD5 specific T cells demonstrate a phenotype and proliferation potential that would support HIV infection. These results are pertinent to the findings of the step study. That's the Merck study from 2007 and future use of AD5 as a vaccine vector. They also say, the T cells expand rapidly following antigen stimulation resulting in a mean 320-fold expansion in these receptors over seven days. Whoa. I pulled a graph picture of this just to show kind of a visual representation. This is from their study.

The first column there, first column aligns of the CCR-5 receptor, and then the second column is the alpha-4 beta-7. And at the bottom, it says day zero and day seven. So you notice at day zero, when they stimulate this antigen with the adenovirus five, you see it all, every one of them moves up. Every one of them expresses a higher percentage of these receptors on their surface, except one of them, which goes down. But the majority of them go up.

And again, it's a 320-fold expansion over seven days. That's what they found. And these are the target cells for HIV infection. So let's bring this home, because I know a lot of viewers are saying, well, what vaccines have this AD5 in there? I want to know right now. So right now, we only have China's cancino biologics. They use the AD5 vector. Russia's Sputnik uses the AD 26 for the first dose and AD5 for the second dose.

Johnson and Johnson uses the adenovirus 26, and AstraZeneca uses a Dinovirus. chimpanzee cold viral vector. But here's where this starts to tie together. There's not a lot of research on cross-reactivity. So we found this study here, which may provide some link. It doesn't have to do specifically with HIV, but it does show that adenoviruses are cross-reactive with each other. So extensive cross-reactivity of CD4 plus adenovirus-specific T-cells, implications for immunotherapy and gene therapy. Remember, a lot of people are saying these vaccines are gene therapy. But they're basically saying that if you use an adenavirus-5, that can cross-react with an adenovirus. You know, there's over 50.

Well, the truth is, is the studies were all done. We're looking at older studies, looking at the deenovirus five being used. We don't know of 26, but there's no studies there. And what they're saying, there could be a cross-reactivity. You could have that problem. Then brings in Johnson-Johnson, Johnson. Astiseneca being used all around the world. It's, you know, really amazing research, Jeffrey,

this and I want to point out too to everyone in our audience there's a couple of things right now if you're brand new to this show you're thinking man that's like a lot of science I feel like I'm in biology class again and I'll tell you I you know I'm a CBS producer that I started my executive producer we both won Emmy Awards for the work that we've done in science in medicine and everyone told us you can never do a show that gets that deep in the weeds well that's what we're doing we're being accused of spreading misinformation but ask yourself what's the last time you actually saw a study a headline and gotten the

with graphs on CNN or MSNBC. This is how we do it here. And hang in there. We'll make other things entertaining. But for all of you that really want to know the truth, this is an investigation that needs to happen. Do you see what we're talking about here? There were warnings that these vaccines could increase the risk of HIV.

And now we're seeing headlines all over the country. Look out, all over the world. Look out. We may be having a rise in HIV. You may want to get out and get tested. Do you see the writing on the wall? I mean, do these connect? We don't know.

This is what I want to say. But we are beginning the investigation. In fact, we began this investigation nearly two years ago. I just wanted to make that point clear one more time because we know we're going to get attacked by the fact checkers that just have this religious belief that all vaccines, even when they're not tested, are perfectly safe. Right.

And, you know, we're also just connecting dots as well. And a lot of people can ask the same questions. This is the final dot to connect. The Moderna has come out, and they have vaccinated their first patients in a clinical trial. So the first patients vaccinated in clinical trial, the HIV experimental vaccine that uses Moderna's mRNA technology. So remember, Mardana was a kind of a nothing burger company. It was floundering. It was infused with a lot of government money. Comes out with a vaccine. Their higher-ups, their CEO, their CFO,

their scientific officer, almost all of them, you know, multimillionaires, billionaires. Some of them left the company. And now they're going from COVID vaccines into HIV experimental vaccines, one of the hardest vaccines to really pull off. It seems, it seems interesting that this would be happening right now. And, you know, unfortunately, our good friend who we were just talking about having on Luke Montenier. Yeah, we were just talking to him about coming on. Great Nobel Prize winning discover of HIV. We were in conversations to have him come forward. He had real concerns about this vaccine. He just passed away last week. Really, really tragic. Yeah, yeah. And of course, He led the team in 1983 who first identified HIV Nobel Prize winner, and our thoughts and prayers go out to his family.

But this is a lot of information. This is an ongoing investigation. We'll bring to you the truth as we find it every week.